Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gsk Plc ADR
(NY:
GSK
)
41.35
+0.47 (+1.15%)
Official Closing Price
Updated: 7:00 PM EDT, Jun 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gsk Plc ADR
< Previous
1
2
3
4
5
6
7
8
9
...
29
30
Next >
3 Undervalued Small-Cap Stocks to Add to Your Must-Buy List
February 22, 2024
Undervalued small-cap stocks are great for investors seeking options for upside potential, typically at a cheap share price.
Via
InvestorPlace
Why Range-Bound Moderna Could Get A Boost On Its Fourth-Quarter Report
February 22, 2024
The company unexpectedly came in with fourth-quarter earnings that beat projections.
Via
Investor's Business Daily
Moderna Stock Q4 Earnings Preview: RSV mRNA Vaccine Scrutiny, Diminishing Spikevax Revenue, FDA Approval In Focus
February 21, 2024
Moderna reports Q4 earnings on Feb. 22. Analysts expect $2.53B in revenue. Stock has faced challenges but potential for recovery with COVID-19 vaccine and FDA approval in 2024.
Via
Benzinga
Exposures
COVID-19
Product Safety
3 Low-Priced Dividend Stocks With Solid Fundamentals & Growth
February 21, 2024
Solid dividend stocks with good growth outlooks can deliver high profits for investors and should become more popular as interest rates drop.
Via
InvestorPlace
Dividend Income Update January 2024
February 15, 2024
It’s dividend income update time. One of my favorite times of the month as I get to review my previous month of passive income received from my dividend income portfolio
Via
Talk Markets
Looking Into GSK's Recent Short Interest
February 12, 2024
Via
Benzinga
Recap: GSK Q4 Earnings
January 31, 2024
Via
Benzinga
Earnings Outlook For GSK
January 30, 2024
Via
Benzinga
A Look Into GSK Inc's Price Over Earnings
January 26, 2024
Via
Benzinga
Why Is Moderna Stock Trading Lower Today?
February 09, 2024
Moderna long term data indicates a faster decline in efficacy for its RSV vaccine than the RSV vaccines from GSK and Pfizer.
Via
Benzinga
Jim Cramer Expects Drugmaker Stock To Go 'Even Higher,' As For Kroger: 'What The Heck Is Going On?'
February 06, 2024
On CNBC’s "Mad Money Lightning Round," Jim Cramer believes in GSK plc (NYSE: GSK).
Via
Benzinga
The 7 Best Healthcare Stocks to Invest In for Big Gains in 2024
February 06, 2024
Invest in the future with healthcare stocks 2024; offering a blend of market stability and cutting-edge medical advancements.
Via
InvestorPlace
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
February 02, 2024
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
What the Options Market Tells Us About GSK
January 09, 2024
Via
Benzinga
Novavax's Malaria Vaccine Gets WHO Prequalification, Has Potential Of Being An Affordable Option
February 02, 2024
Novavax's R21/Matrix-M malaria vaccine, with 75% efficacy in seasonal areas. Affordable at $3 per dose, it outshines GSK's vaccine. Global rollout expected mid-2024.
Via
Benzinga
Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review
February 02, 2024
The Dow led the major indexes higher. Big techs diverged on results.
Via
Investor's Business Daily
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
What's Going On With GSK Stock Today?
February 01, 2024
GSK settles U.S. Zantac lawsuit, avoiding trial. Confidential settlements reinforce commitment to legal efficiency.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Teva Sinks On Lackluster Profit Outlook Despite Walloping Quarterly Projections
January 31, 2024
Teva Pharmaceutical easily beat fourth-quarter views, but its 2024 profit guidance left something to be desired.
Via
Investor's Business Daily
GSK Upgrades Long-Term Outlook After Q4 Performance, Shingrix Vaccine And Newly Launched RSV Vaccine Shine
January 31, 2024
GSK's robust Q4 performance with a 21% YoY increase in adjusted operating profit. Arexvy vaccine sales hit £1.2B in 2023. Outlook for 2024, with 5%-7% sales growth and upgraded long-term projections.
Via
Benzinga
Nasdaq Futures Plummet As Alphabet, AMD Disappointments Sour Sentiment; Spotlight Shifts To Fed Statement, Powell's Presser
January 31, 2024
The record run of the market faces risk as the big tech earnings season got off to a negative start, casting cloud on profit outlook.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60%
January 30, 2024
Explore the impact of the U.S. government's proposal on pharmaceuticals! Learn about Medicare's negotiation power, potential price cuts, and industry reactions.
Via
Benzinga
Earnings Scheduled For January 31, 2024
January 31, 2024
Companies Reporting Before The Bell • Novartis (NYSE:NVS) is likely to report quarterly earnings at $1.68 per share on revenue of $11.56 billion.
Via
Benzinga
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
January 29, 2024
An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
GSK Cuts More Stake In Its Spun-Off Consumer-Healthcare Business Haleon, Raises Over £900M
January 17, 2024
GSK sells 300M shares in Haleon at £326/share, raising £978M. GSK to retain 4.2% stake.
Via
Benzinga
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
January 13, 2024
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will...
Via
Talk Markets
Pfizer's Aggressive Stance In Obesity Drugs: CEO Albert Bourla Confirms Bold Bet Despite Prior Drug Hurdles
January 09, 2024
Monday, at the JP Morgan Healthcare Conference, Pfizer Inc (NYSE: PFE) CEO Albert Bourla expressed that the company is determined to move forward in the burgeoning
Via
Benzinga
GSK Boosts Its Asthma Product Portfolio With Over $1B Deal For Aiolos Bio
January 09, 2024
GSK plc (NYSE: GSK) has agreed to acquire Aiolos Bio Inc
Via
Benzinga
Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada
January 05, 2024
The FDA has allowed Florida to import prescription drugs from Canada, potentially altering the landscape of how Americans access and afford their medications.
Via
Benzinga
Exposures
Product Safety
Why Biopharmaceutical Player CureVac Shares Are Rising Today
January 05, 2024
CureVac N.V. (NASDAQ: CVAC) shares are trading higher on Friday.
Via
Benzinga
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
...
29
30
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.